The introduction of texture to the outer shell of breast implants was aimed at increasing tissue incorporation and reducing capsular contracture. It has also been shown that textured surfaces promote a higher growth of bacteria and are linked to the development of breast implant–associated anaplastic large cell lymphoma.
The authors aimed to measure the surface area and surface roughness of 11 available implants. In addition, the authors aimed to subject these implant shells to an in vitro bacterial attachment assay with four bacterial pathogens (Staphylococcus epidermidis, S. aureus, Pseudomonas aeruginosa, and Ralstonia pickettii) and study the relationship among surface area, surface roughness, and bacterial growth.
Surface area measurement showed grouping of implants into high, intermediate, low, and minimal. Surface roughness showed a correlation with surface area. The in vitro assay showed a significant linear relationship between surface area and bacterial attachment/growth. The high surface area/roughness implant texture grew significantly more bacteria at 24 hours, whereas the minimal surface area/roughness implant textures grew significantly fewer bacteria of all types at 24 hours. For implants with intermediate and low surface areas, some species differences were observed, indicating possible affinity of specific bacterial species to surface morphology.
Implant shells should be reclassified using surface area/roughness into four categories (high, intermediate, low, and minimal). This classification is superior to the use of descriptive terms such as macrotexture, microtexture, and nanotexture, which are not well correlated with objective measurement and/or functional outcomes.
This and Related “Classic” Articles Appear on Prsjournal.com for Journal Club Discussions.
Sydney, New South Wales, Australia; and Dallas, Texas
From the Surgical Infection Research Group, Faculty of Medical and Health Sciences, Macquarie University; Integrated Specialist Healthcare Education and Research Foundation; Monash University; Australian Center for Microscopy and Microanalysis, University of Sydney; and the University of Texas Southwestern.
Received for publication December 28, 2017; accepted March 30, 2018.
Disclosure: Professor Deva is research coordinator and consultant to Allergan, Mentor (Johnson & Johnson), Sientra, Motiva, and Acelity. Associate Professor Vickery is research coordinator and consultant to Allergan, Mentor (Johnson & Johnson), and Acelity.
Supplemental digital content is available for this article. Direct URL citations appear in the text; simply type the URL address into any Web browser to access this content. Clickable links to the material are provided in the HTML text of this article on the Journal’s website (www.PRSJournal.com).
Anand K. Deva, B.Sc.(Med.), M.B.B.S., M.S., Suite 301, 2 Technology Place, Macquarie Park, New South Wales 2109, Australia, email@example.com